Good results. An over-looked stock although it was flagged up by Shares magazine a couple of months ago. Revenues up and trials proceeding this year means there should be plenty of newsflow.

http://www.uk-wire.com/cgi-bin/articles/200503080700074388J.html

Very difficult to buy any size online but MM's will bid for 50,00O

11 July 2007

Allergy Therapeutics plc
('Allergy Therapeutics' or 'the Company')

Clinical Development Update


Allergy Therapeutics announces that clinical activity on its Pollinex Quattro
clinical studies has been placed on clinical hold by the FDA whilst the agency
fully assesses the report of a rare adverse event classified by the physician
involved as 'possibly related' to the study drug.


The Company is collaborating fully with the FDA and has provided extensive data,
both as part of the trial routine and supplementary data, including independent
expert assessment. Allergy Therapeutics has also reviewed all the data
available to it concerning this adverse event, considers that it is unlikely
that the event was caused by the study drug and is urgently working with the FDA
to provide any additional information necessary to address and resolve FDA's
concerns.


Allergy Therapeutics has two ongoing Pollinex Quattro studies: Phase III Grass
(G301) and Phase III Ragweed (R301), and has two about to commence/recommence:
the Grass safety study (G302) and a Phase II Tree study (T204). Of these only
R301 is directly affected as it is the only trial in the treatment phase.


A full update will be provided as soon as the FDA gives material information on
the results of its review.


Keith Carter, Chief Executive of Allergy Therapeutics, said:


'The FDA has a difficult job to do in minimising risk to patients, both on
clinical trials and from marketed pharmaceuticals. It is normal that they
should exercise caution. We believe the evidence strongly supports the view
that the event was unlikely to have been caused by Pollinex Quattro and we are
seeking urgent clarification of the FDA's position.'


There will be a conference call for analysts at 11.00am.
Please dial +44 (0)20 7138 0843 to access the call.

This could be a good opportunity to buy into this stock which is in late stage development of R301. I wouldn't be surprised to see this recover well on clarification of the FDA's report. In all probability this is unrelated or the patient would suffer these reactions when in the prescence of ragweed pollen or the antigens on it.

Have added a chart.

FDA lifts clinical hold on Allergy Therapeutics' vaccine
StockMarketWire.com
The US Food and Drug Administration has lifted the clinical hold on Allergy Therapeutics' grass pollen allergy vaccine development programme.

Allergy Therapeutics has gained approval to progress with a phase III efficacy study on the vaccine (Grass MATA MPL/Pollinex Quattro Grass 0.5ml) to be conducted in an environmental exposure chamber.

Allergy Therapeutics is now focused on securing a partner to commercialise Pollinex Quattro in the US.

Chief executive Manuel Llobet said: "We are pleased that the FDA has decided to lift the clinical hold on our Pollinex Quattro programme.

"This product has the potential to greatly benefit allergy sufferers in the US in the absence of registered products by being the first subcutaneous immunotherapy vaccine to reach the US market.

"Additionally, lifting of the hold will allow for discussions with potential partners with whom we will finalise the clinical development and

8% rise today

Worth keeping an eye on perhaps, seems to be staging a recovery and Interim Results out on Monday.

Bought a few. If the Interims are good this could get back to 40p pretty quick and if the Interims are not as good as expected it could drop back to about 20p. imo

Just for interest for any golfers holding this share, Bubba Watson had a nightmare first round at the Arnold Palmer Invitational and blamed pollen allergies. I suppose it makes a change from blaming your golf clubs!!!

After a win at last month’s Northern Trust Open and that tie alongside Donaldson at Doral, Bubba Watson came in as one of the favourites.

But the 2012 Masters champion withdrew after an 83, which included an 11 on the par-five sixth (his 15th) where he hit three balls into the water. Watson cited allergies, tweeting: “It’s hard to focus when you’re heads all discombobulated from medicine and pollen.”

(Daily Telegraph)

Allergy grows profits
StockMarketWire.com
Allergy Therapeutics' operating profits rose by 26% to £6.7m in the six months to end-December. The group saw continued improvement in its European market share.

Gross revenues - excluding milestones and rebates - rose to £29.9m from £26.6m in 2013 and gross profit increased 11% to £20.7m.

Chief executive Manuel Llobet said: "We have reported a strong financial performance for the period underpinned by a marked increase in market share in the key European territories in which we operate such that we completed the half-year with an overall share increase of 12% in the allergy segment.

"We have also made significant progress improving our product portfolio during the period including the launch of our probiotics product range and Acarovac, a mite allergoid product. We initiated a phase II clinical programme for Pollinex Quattro Birch, and in Germany we are proceeding with the registration of the Pollinex Quattro Grass MATA MPL (1.0ml).

"In North America, post period end, the Canadian Health Authority approved the submission of our Clinical Trial Application (CTA) for a new environmental challenge chamber study with Pollinex Quattro Grass MATA MPL (0.5ml). The recent positive developments in the US allergy regulatory environment underscore our confidence that North America will emerge as a valuable market for registered allergy vaccines. We continue to explore our strategic options for the development and commercialisation of Pollinex Quattro in this territory."

Who Should Attend?Date:

Tuesday 22nd September 2015

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:Sponsored by: